Late toxicity after postprostatectomy salvage radiation therapy

Jennifer L. Peterson, Steven J. Buskirk, Michael G. Heckman, Juliana Crook, Stephen J. Ko, Michael J. Wehle, Todd C. Igel, Karin A. Prussak, Thomas M. Pisansky

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP). Methods: A cohort of 308 consecutive patients underwent salvage EBRT from July 1987 through June 2003 for a detectable PSA level after RP. All were treated with high-energy photons (6-20 MV) to a median dose of 64.8 Gy (range: 54.0-72.4 Gy) in 1.8- to 2.0-Gy fractions. Results: Median follow-up from the completion of EBRT was 60 months (range: 1 day-174 months). Late toxicity occurring more than 90 days after EBRT completion was identified in 41 patients (13%). Twelve patients (3.9%) had grade 2 urethral strictures and were treated with urethral dilation, 3 patients had grade 3 cystitis, and 1 had a grade 4 rectal complication. These numbers correspond to an estimated 0.7% (95% confidence interval, 0.0-1.6%) of patients experiencing a grade 3 or 4 complication by 5 years after the start of EBRT. Conclusions: Salvage EBRT for a detectable PSA level after RP is the only curative treatment in this setting. This treatment can be administered in a manner that results in a low likelihood of late complications.

Original languageEnglish (US)
Pages (from-to)203-206
Number of pages4
JournalRadiotherapy and Oncology
Volume93
Issue number2
DOIs
StatePublished - Nov 2009

Fingerprint

Salvage Therapy
Radiotherapy
Prostate-Specific Antigen
Prostatectomy
Urethral Stricture
Cystitis
Photons
Dilatation
Confidence Intervals
Therapeutics

Keywords

  • Adjuvant therapy
  • Prostate-specific antigen
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Peterson, J. L., Buskirk, S. J., Heckman, M. G., Crook, J., Ko, S. J., Wehle, M. J., ... Pisansky, T. M. (2009). Late toxicity after postprostatectomy salvage radiation therapy. Radiotherapy and Oncology, 93(2), 203-206. https://doi.org/10.1016/j.radonc.2009.08.035

Late toxicity after postprostatectomy salvage radiation therapy. / Peterson, Jennifer L.; Buskirk, Steven J.; Heckman, Michael G.; Crook, Juliana; Ko, Stephen J.; Wehle, Michael J.; Igel, Todd C.; Prussak, Karin A.; Pisansky, Thomas M.

In: Radiotherapy and Oncology, Vol. 93, No. 2, 11.2009, p. 203-206.

Research output: Contribution to journalArticle

Peterson, JL, Buskirk, SJ, Heckman, MG, Crook, J, Ko, SJ, Wehle, MJ, Igel, TC, Prussak, KA & Pisansky, TM 2009, 'Late toxicity after postprostatectomy salvage radiation therapy', Radiotherapy and Oncology, vol. 93, no. 2, pp. 203-206. https://doi.org/10.1016/j.radonc.2009.08.035
Peterson, Jennifer L. ; Buskirk, Steven J. ; Heckman, Michael G. ; Crook, Juliana ; Ko, Stephen J. ; Wehle, Michael J. ; Igel, Todd C. ; Prussak, Karin A. ; Pisansky, Thomas M. / Late toxicity after postprostatectomy salvage radiation therapy. In: Radiotherapy and Oncology. 2009 ; Vol. 93, No. 2. pp. 203-206.
@article{f51a5f942b7c4aa69bbbb9126eabe6fe,
title = "Late toxicity after postprostatectomy salvage radiation therapy",
abstract = "Purpose: To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP). Methods: A cohort of 308 consecutive patients underwent salvage EBRT from July 1987 through June 2003 for a detectable PSA level after RP. All were treated with high-energy photons (6-20 MV) to a median dose of 64.8 Gy (range: 54.0-72.4 Gy) in 1.8- to 2.0-Gy fractions. Results: Median follow-up from the completion of EBRT was 60 months (range: 1 day-174 months). Late toxicity occurring more than 90 days after EBRT completion was identified in 41 patients (13{\%}). Twelve patients (3.9{\%}) had grade 2 urethral strictures and were treated with urethral dilation, 3 patients had grade 3 cystitis, and 1 had a grade 4 rectal complication. These numbers correspond to an estimated 0.7{\%} (95{\%} confidence interval, 0.0-1.6{\%}) of patients experiencing a grade 3 or 4 complication by 5 years after the start of EBRT. Conclusions: Salvage EBRT for a detectable PSA level after RP is the only curative treatment in this setting. This treatment can be administered in a manner that results in a low likelihood of late complications.",
keywords = "Adjuvant therapy, Prostate-specific antigen, Radiotherapy",
author = "Peterson, {Jennifer L.} and Buskirk, {Steven J.} and Heckman, {Michael G.} and Juliana Crook and Ko, {Stephen J.} and Wehle, {Michael J.} and Igel, {Todd C.} and Prussak, {Karin A.} and Pisansky, {Thomas M.}",
year = "2009",
month = "11",
doi = "10.1016/j.radonc.2009.08.035",
language = "English (US)",
volume = "93",
pages = "203--206",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Late toxicity after postprostatectomy salvage radiation therapy

AU - Peterson, Jennifer L.

AU - Buskirk, Steven J.

AU - Heckman, Michael G.

AU - Crook, Juliana

AU - Ko, Stephen J.

AU - Wehle, Michael J.

AU - Igel, Todd C.

AU - Prussak, Karin A.

AU - Pisansky, Thomas M.

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP). Methods: A cohort of 308 consecutive patients underwent salvage EBRT from July 1987 through June 2003 for a detectable PSA level after RP. All were treated with high-energy photons (6-20 MV) to a median dose of 64.8 Gy (range: 54.0-72.4 Gy) in 1.8- to 2.0-Gy fractions. Results: Median follow-up from the completion of EBRT was 60 months (range: 1 day-174 months). Late toxicity occurring more than 90 days after EBRT completion was identified in 41 patients (13%). Twelve patients (3.9%) had grade 2 urethral strictures and were treated with urethral dilation, 3 patients had grade 3 cystitis, and 1 had a grade 4 rectal complication. These numbers correspond to an estimated 0.7% (95% confidence interval, 0.0-1.6%) of patients experiencing a grade 3 or 4 complication by 5 years after the start of EBRT. Conclusions: Salvage EBRT for a detectable PSA level after RP is the only curative treatment in this setting. This treatment can be administered in a manner that results in a low likelihood of late complications.

AB - Purpose: To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP). Methods: A cohort of 308 consecutive patients underwent salvage EBRT from July 1987 through June 2003 for a detectable PSA level after RP. All were treated with high-energy photons (6-20 MV) to a median dose of 64.8 Gy (range: 54.0-72.4 Gy) in 1.8- to 2.0-Gy fractions. Results: Median follow-up from the completion of EBRT was 60 months (range: 1 day-174 months). Late toxicity occurring more than 90 days after EBRT completion was identified in 41 patients (13%). Twelve patients (3.9%) had grade 2 urethral strictures and were treated with urethral dilation, 3 patients had grade 3 cystitis, and 1 had a grade 4 rectal complication. These numbers correspond to an estimated 0.7% (95% confidence interval, 0.0-1.6%) of patients experiencing a grade 3 or 4 complication by 5 years after the start of EBRT. Conclusions: Salvage EBRT for a detectable PSA level after RP is the only curative treatment in this setting. This treatment can be administered in a manner that results in a low likelihood of late complications.

KW - Adjuvant therapy

KW - Prostate-specific antigen

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=70350515449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350515449&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2009.08.035

DO - 10.1016/j.radonc.2009.08.035

M3 - Article

VL - 93

SP - 203

EP - 206

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -